REFERENCES
- Nyholm S, Thelander L, Gräslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry. 1993;32(43):11569–11574.
- Nigović B, Kujundzić N, Sanković K. Electron transfer in N-hydroxyurea complexes with iron (III). Eur J Med Chem. 2005;40(1):51–55.
- Dubacq C, Chevalier A, Courbeyrette R, Petat C, Gidrol X, Mann C. Role of the iron mobilization and oxidative stress regulons in the genomic response of yeast to hydroxyurea. Mol Genet Genom.. 2006;275(2):114–124.
- Oblender M, Carpentieri U. Effects of iron, copper and zinc on the activity of ribonucleotide reductase in normal and leukemic human lymphocytes. Anticancer Res. 1990;10(1):123–127.
- Testa EP, Testa U, Samoggia P, Salvo G, Camagna A, Peschle C. Expression of transferrin receptors in human erythroleukemic lines: regulation in the plateau and exponential phase of growth. Cancer Res. 1986;46(10):5330–5334.
- Sakano K, Oikawa S, Hasegawa K, Kawanishi S. Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res. 2001;92(11):1166–1174.
- King SB. Nitric oxide production from hydroxyurea. Free Radic Biol Med. 2004;15;37(6):737–744.
- Lou TF, Singh M, Mackie A, Li W, Pace BS. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med (Maywood). 2009;234 (11):1374–1382.
- Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184–191.
- Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood. 1994;83(2):553–560.
- Kontoghiorghes GJ, Efstathiou A, Ioannou-Loucaides S, Kolnagou A. Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment. Hemoglobin. 2008;32(1–2):217–227.
- Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663–2681.
- Pashalidis I, Kontoghiorghes GJ. Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Arzn Forsch/Drug Res. 2001;51(II):998–1003.
- Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006;7(6):639–651.
- Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23):2695–2709.
- Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin. 2008;32(1–2):229–236.
- Voskaridou E, Christoulas D, Bilalis A, . The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363.